Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Herc who wrote (3589)	8/16/1999 6:24:00 AM
From: BMcV	Read Replies (2) of 10280

>>This company is offering generics with a difference, and there won't be enough difference to warrant a price premium.<< You are a fool. How can you call Allegra "a generic" of Seldane, given that the former avoids the potentially fatal cardiac effects of the latter? Have you ever heard of the FDA mandating a switch from the "name" brand to the the "generic", as they have done in the case of Seldane/Allegra? Several other drugs in SEPRs patent portfolio fit this model (norastemizole, norcisapride). Any one of them could justify the current market capitalization of the company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next